The european hematology association roadmap for european hematology research: A consensus document

62Citations
Citations of this article
230Readers
Mendeley users who have this article in their library.

Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

References Powered by Scopus

Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

21403Citations
N/AReaders
Get full text

Continuous cultures of fused cells secreting antibody of predefined specificity

13504Citations
N/AReaders
Get full text

Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma

4897Citations
N/AReaders
Get full text

Cited by Powered by Scopus

CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia

1144Citations
N/AReaders
Get full text

Gene therapy in patients with transfusion-dependent β-thalassemia

554Citations
N/AReaders
Get full text

Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference

96Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., … Zieger, B. (2016). The european hematology association roadmap for european hematology research: A consensus document. Haematologica, 101(2), 115–208. https://doi.org/10.3324/haematol.2015.136739

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 52

46%

Researcher 28

25%

Professor / Associate Prof. 27

24%

Lecturer / Post doc 6

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 55

49%

Biochemistry, Genetics and Molecular Bi... 29

26%

Agricultural and Biological Sciences 16

14%

Nursing and Health Professions 12

11%

Article Metrics

Tooltip
Mentions
News Mentions: 264
Social Media
Shares, Likes & Comments: 25

Save time finding and organizing research with Mendeley

Sign up for free